OS Therapies, a clinical-stage immunotherapy and Antibody-Drug Conjugate (ADC) biopharmaceutical company, today announced the completion of its acquisition of the listeria-based cancer immunotherapy assets of Advaxis Immunotherapies from Ayala Pharmaceuticals. This move consolidates OS Therapies' intellectual property and strengthens its position in the cancer immunotherapy market. The acquisition includes several clinical-stage and preclinical immunotherapy programs. OS Therapies aims to drive innovation and improve cancer treatment outcomes through its listeria platform.